Repairing Membranes to Rescue Mitochondria in Degenerative Diseases

Amporin Drug Pipeline

Current Pipeline

Amporin has three early drug discovery programs in Alzheimer's Disease (AD), Type 2 Diabetes (T2D), and Parkinson's Disease (PD). Our lead program targets α-synuclein (αSyn) pores in Parkinson's Disease. Meanwhile, our Alzheimer's and Diabetes drug programs targeting Aβ/tau and IAPP pores are now available for partnering or licensing.

Pipeline Strategy

Amporin plans to develop and license a full pipeline of First-in-Class oral small-molecule drugs for up to six major degenerative diseases, based on its proprietary pore-targeting drug platforms.
The company is focused on identifying and optimizing lead compounds for Parkinson's, Alzheimer's and Diabetes, and plans to develop further drug candidates for Amyotrophic Lateral Sclerosis (ALS), Progressive Supranuclear Palsy (PSP) or Frontotemporal Dementia (FTD), and Huntington's Disease (HD), with the aim of establishing a sustainable pipeline capable of delivering up to one new development candidate each year.

AMP-PD - Parkinson's Disease (αSyn)

  • Drug program: AMP-PD
  • Target disease: Parkinson's disease (PD)
  • Drug target: Toxic pores formed by α-synuclein (αSyn) oligomers
  • Current stage: Screening / Hit Identification
  • Partnering: Available for licensing after Phase 1b / 2a clinical trials

AMP-AD - Alzheimer's Disease (Aβ/tau)

  • Drug program: AMP-AD
  • Target disease: Alzheimer's disease (AD)
  • Drug target: Toxic pores formed by β-amyloid (Aβ) and tau oligomers
  • Current stage: Screening / Hit Identification
  • Partnering: Now available for partnering or licensing

AMP-DM - Type 2 Diabetes (IAPP)

  • Drug program: AMP-DM
  • Target disease: Type 2 diabetes (T2D)
  • Drug target: Toxic pores formed by Amylin / Islet Amyloid Polypeptide (IAPP) oligomers
  • Current stage: Screening / Hit Identification
  • Partnering: Now available for partnering or licensing

Future Drug Programs (options)

  • AMP-ALS: Amyotrophic Lateral Sclerosis (ALS)
  • AMP-PSP: Progressive Supranuclear Palsy (PSP)
  • AMP-FTD: Frontotemporal Dementia (FTD)
  • AMP-HD: Huntington's Disease (HD)

Next

Learn about our Current Partners and Partnering Opportunities to develop the first pore-targeting therapies ...
More >>
© 2026 Amporin Pharmaceuticals AG | Oberwilerstrasse 54, 4054 Basel, Switzerland | Company No. CHE-337.200.500 | VAT No. 052.0378.8099 | Tel. +41 78 749 49 36